Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Curcumin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.89 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.89 |
| ▸ | TLR9 known ✓ | Q9NR96 | 1/20 | 0.89 |
| ▸ | APP | P05067 | 10/20 | 0.89 |
| ▸ | MAPT | P10636 | 9/20 | 0.89 |
| ▸ | BACE1 | P56817 | 5/20 | 0.89 |
| ▸ | MMP9 | P14780 | 4/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.89 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.89 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.89 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.89 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.89 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.89 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.89 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.89 |
| ▸ | STAT3 | P40763 | 2/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Curcumin SCHEMBL19469820 | 1.00 | APP (0.89) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL27712113 | 0.99 | APP (0.86) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL2334244 | 0.96 | APP (0.82) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL8336603 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL8440 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL17629819 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL6901740 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL250984 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL2804734 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 | |
| Curcumin SCHEMBL17629818 | 0.94 | APP (1.00) | APPMAPTBACE1MMP9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594249-B2 | Soluble curcumin and its derivatives | THERMOLIFE INTERNATIONAL, LLC (US) | 2026-04-07 | — | — | US | claimed |
| EP-4606388-A9 | METAL-POLYPHENOL COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF | Hunan Lonstar Biotech Co., Ltd. (CN) | 2026-02-25 | — | — | EP | claimed |
| US-20260048142-A1 | METAL-CHELATED POLYPHENOL COMPLEX NANOPARTICLE, DRUG-LIPID PARTICLE, PREPARATION METHODS FOR THE SAME, AND USES THEREOF | HUNAN LONSTAR BIOTECH CO LTD (CN) | 2026-02-19 | — | — | US | claimed |
| EP-4606388-A1 | METAL-POLYPHENOL COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF | Hunan Lonstar Biotech Co., Ltd. (CN) | 2025-08-27 | — | — | EP | claimed |
| EP-4570271-A1 | METAL-PHOSPHOLIPID COMPLEX, METAL-PHOSPHOLIPID COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF | Hunan Lonstar Biotech Co., Ltd. (CN) | 2025-06-18 | — | — | EP | claimed |
| WO-2024250032-A9 | SOLUBLE CURCUMIN AND ITS DERIVATIVES | THERMOLIFE INTERNATIONAL, LLC (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2024250032-A1 | SOLUBLE CURCUMIN AND ITS DERIVATIVES | THERMOLIFE INTERNATIONAL, LLC (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240398726-A1 | SOLUBLE CURCUMIN AND ITS DERIVATIVES | THERMOLIFE INTERNATIONAL, LLC | 2024-12-05 | — | — | US | claimed |
| US-20240269066-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | PRECVISION BIOTECHNOLOGIES LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| EP-4353264-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | Precvision Biotechnologies Ltd. (CN) | 2024-04-17 | — | — | EP | claimed |
| US-20150377894-A1 | Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin | SIGNPATH PHARMA INC. | 2015-12-31 | — | — | US | claimed |
| US-9170257-B2 | Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin | SIGNPATH PHARMA INC. (US) | 2015-10-27 | — | — | US | claimed |
| EP-2861982-A1 | METHOD AND SYSTEM FOR MEASURING THE PHARMACOKINETICS OF LIPOSOMAL CURCUMIN AND ITS METABOLITE TETRAHYDROCURCUMIN | Signpath Pharma Inc. (US) | 2015-04-22 | — | — | EP | claimed |
| US-8653154-B2 | Synergistic effects of blending multiple additives in UHMWPE | SMITH & NEPHEW, INC. (US) | 2014-02-18 | — | — | US | claimed |
| WO-2013188767-A1 | METHOD AND SYSTEM FOR MEASURING THE PHARMACOKINETICS OF LIPOSOMAL CURCUMIN AND ITS METABOLITE TETRAHYDROCURCUMIN | SIGNPATH PARMA, INC. (US) | 2013-12-19 | — | — | WO | claimed |
| US-20130337488-A1 | Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin | SIGNPATH PHARMA INC. | 2013-12-19 | — | — | US | claimed |
| EP-2427225-A2 | SYNERGISTIC EFFECTS OF BLENDING MULTIPLE ADDITIVES IN UHMWPE | Smith&Nephew, Inc. (US) | 2012-03-14 | — | — | EP | claimed |
| US-20120046380-A1 | SYNERGISTIC EFFECTS OF BLENDING MULTIPLE ADDITIVES IN UHMWPE | SMITH & NEPHEW, INC. (US) | 2012-02-23 | — | — | US | claimed |
| WO-2010129514-A2 | SYNERGISTIC EFFECTS OF BLENDING MULTIPLE ADDITIVES IN UHMWPE | SMITH & NEPHEW, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| US-20080031980-A1 | Curcumin-containing composition, methods of making, and methods of using | FARR LABORATORIES, LLC | 2008-02-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398726-A1 | SOLUBLE CURCUMIN AND ITS DERIVATIVES | GOT1, GOT2, OAT | MAOA 3323/4885MAOB 2726/4885TLR9 2714/4885 |
| US-20260048142-A1 | METAL-CHELATED POLYPHENOL COMPLEX NANOPARTICLE, DRUG-LIPID PARTICLE, PREPARATION METHODS FOR THE SAME, AND USES THEREOF | HAMP, ELP1, LIPC | MAOA 3439/4885MAOB 3963/4885TLR9 777/4885 |
| US-12594249-B2 | Soluble curcumin and its derivatives | SLC2A8, SLC2A2, SLC2A1 | MAOA 660/4885MAOB 1325/4885TLR9 4324/4885 |
| US-20150377894-A1 | Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin | TTPA, PLPBP, HAMP | MAOA 3441/4885MAOB 3058/4885TLR9 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.